Myeloproliferative Neoplasms

Prithviraj Bose, MD, discusses the current role of ruxolitinib in myelofibrosis, the potential advantages of next-generation JAK inhibitors, and the novel agents that are being explored as single agents and in combination with ruxolitinib. 

The International Working Group for the Prognosis of MDS has identified a distinct subtype of myelodysplastic syndromes based on the presence of SF3B1, a nonheritable genetic mutation that causes the disease.

Laura C. Michaelis, MD, discusses the role of interferon in myeloproliferative neoplasms.

A European panel has recommended approval of luspatercept for the treatment of anemia in patients with myelodysplastic syndromes and beta thalassemia.

Terrence J. Bradley, MD, discusses the utility of ruxolitinib (Jakafi) in myelofibrosis and polycythemia vera.

Shella Saint Fleur-Lominy, MD, PhD, discusses the current sequencing strategy in the treatment of patients with myeloproliferative neiplasms.

Terrence J. Bradley, MD, discusses the challenges of treating patients with myeloproliferative neoplasms.

Jorge E. Cortes, MD, director of the Georgia Cancer Center at Augusta University, discusses the challenges of using ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms (MPNs).

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.

Laura C. Michaelis, MD, discusses potential combination strategies with ruxolitinib in myelofibrosis.

Ruben Mesa, MD, discusses the use of ruxolitinib versus fedratinib in patients with myelofibrosis and baseline thrombocytopenia.

Alvin H. Schmaier, MD, professor in the Department of Medicine and the Department of Pathology at Case Western Reserve University School of Medicine, discusses the management of patients with cancer-associated thrombosis.

Terrence J. Bradley, MD, discusses the evolution of therapeutic strategies in myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses the current state of ET treatment, the challenges of diagnosing the disease, and available educational resources for healthcare providers and patients.

Jorge E. Cortes, MD, discusses managing treatment toxicities to optimize therapeutic outcomes in patients with CML and MPNs.

Naveen Pemmaraju, MD, discusses the need for collaboration when diagnosing and treating patients with myelofibrosis.

Ruben Mesa, MD, discusses unanswered questions regarding JAK inhibitors in myelofibrosis.

James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Laura C. Michaelis, MD, discusses the direction of future myelofibrosis research.

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Shella Saint Fleur-Lominy, MD, PhD, discusses remaining challenges in myelofibrosis.

Ruben Mesa, MD, discusses remaining challenges in treating myelofibrosis.